GlassScriptPhysician profile
Worood Abboud
NPI 1245325018
$14,772.75
in general payments reported to CMS, 2019-2025
89 companies · $3,695 in 2025
The $3,695 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,502 · 2020: $1,171 · 2021: $3,254 · 2022: $1,356 · 2023: $1,311 · 2024: $2,484 · 2025: $3,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,924 · Long Term Medical Supply Or Device Loan: $565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,924.31 |
| Long Term Medical Supply Or Device Loan | $565.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,709.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $749.45 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $718.77 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $711.95 | 2019-2025 | Opdivo, Eliquis, Opdualag |
| Abbvie INC. | $637.38 | 2019-2025 | Venclexta |
| Pfizer INC. | $587.71 | 2019-2025 | |
| Janssen Biotech, INC. | $518.90 | 2019-2025 | Erleada, Carvykti, Darzalex |
| Tersera Therapeutics LLC | $502.08 | 2019-2025 | Xermelo, Zoladex |
| Lilly USA, LLC | $427.06 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Eisai INC. | $422.15 | 2019-2025 | |
| Genentech USA, INC. | $400.30 | 2019-2025 | Tecentriq Hybreza, Venclexta, Polivy |
| Takeda Pharmaceuticals U.S.A., INC. | $365.14 | 2019-2025 | Ninlaro, Iclusig, Hyqvia |
| Gilead Sciences, INC. | $339.45 | 2019-2025 | Trodelvy |
| Daiichi Sankyo INC. | $326.61 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Celgene Corporation | $315.34 | 2019-2025 | Reblozyl, Breyanzi, Pomalyst |
Show all 89 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Worood Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.